12.07.2023 – 08:48
STADA Arzneimittel AG
Bad Vilbel
STADA buys established consumer healthcare brands from Sanofi in numerous countries including Belgium, Germany, Hungary, Spain, Great Britain and Sweden. The portfolio includes brands such as Antistax, Lomudal, Omnivit and Opticrom for the treatment of venous insufficiency and allergies as well as other indications that optimally complement STADA’s CHC footprint. STADA CEO Peter Goldschmidt: “We are very pleased to continue our cooperation with Sanofi. This acquisition further strengthens STADA’s position as one of the four leading providers in the European consumer healthcare market and accelerates our growth path in line with our mission ‘Caring for People’s Health as a Trusted Partner'”.
STADA once again acquires established and leading local consumer healthcare brands from Sanofi, thereby expanding its portfolio in European markets including Belgium, Germany, Hungary, Spain, Great Britain and Sweden. In Germany, the company will in future be responsible for the entire range of the well-known Antistax brand for vein disorders. The portfolio includes vein tablets, vein cream and the fresh gel in various pack sizes.
The transaction also includes other European brands such as Omnivit vitamins and the allergy eye drops Lomudal and Opticrom. The acquired portfolio also includes the two painkillers AAS and Dolalgial as well as Bila-Git for gallbladder problems. The transaction is expected to close in the fourth quarter of 2023, will be funded from cash flow and existing debt and is subject to customary regulatory approvals.
STADA CEO Peter Goldschmidt: “We are very pleased to continue our cooperation with Sanofi. This acquisition further strengthens STADA’s position as one of the four leading providers in the European consumer healthcare market and accelerates our growth path in line with our mission ‘Caring for People’s Health as a Trusted Partner.”
“As a broad-based European player with a strong presence in the local markets, STADA is a partner of choice in the consumer healthcare sector,” emphasizes Goldschmidt. “The acquired brands and their geographical presence are well aligned with the organic activities in STADA’s core countries and generate synergies.”
STADA Head of Western Europe and Germany Stephan Eder adds: “This acquisition is another important step for STADA to expand the market leadership of strong local brands. On the basis of our comprehensive sales and marketing network throughout Europe and our long-standing partnership with pharmacists, we will have several brands with further expand additional services. With the further development of these well-known products, we are strengthening our broad range for customers within our three strategic pillars Consumer Healthcare, Specialty Pharmaceuticals and Generics in important – predominantly Western European – markets.”
The acquisition of additional consumer healthcare brands from Sanofi is the latest example of continued and successful business development. In 2021, STADA already acquired 16 brands from Sanofi and in 2022 concluded an agreement for the distribution of Sanofi’s consumer healthcare portfolio in 10 countries in Central Asia. In addition, STADA had already acquired 15 established consumer healthcare brands from GSK in more than 40 countries and numerous therapeutic areas in 2020. In the same year, STADA expanded its portfolio of dietary supplements through the acquisition of the Czech healthcare company Walmark, which has an international presence.
Previous milestones of STADA in the Consumer Healthcare segment:
February 2020 – STADA acquires 15 established brands from GSK and thus becomes one of the most important players in the consumer healthcare sector March 2020 – STADA completes acquisition of Walmark and thus expands successful portfolio in Eastern Europe June 2021 – STADA expands European consumer healthcare portfolio through the acquisition of 16 established brands from Sanofi July 2021 – STADA and Sanofi sign distribution agreement for consumer healthcare in selected European countries November 2022 – STADA and Sanofi sign distribution agreement for consumer healthcare in Eurasian countries
About STADA Arzneimittel AG
STADA Arzneimittel AG is based in Bad Vilbel, Hesse. The company relies on a three-pillar strategy consisting of consumer healthcare products, generics and specialty pharmaceuticals. STADA Arzneimittel AG sells its products in around 120 countries worldwide. In financial year 2022, STADA achieved consolidated sales of EUR 3,797.2 million and earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 884.7 million. As of December 31, 2022, STADA employed 13,183 people worldwide.
Press contact:
More information for journalists:
STADA Arzneimittel AG
Media Relations
Stadastraße 2-18
61118 Bad Vilbel
Tel.: +49 (0) 6101 603-165
Fax: +49 (0) 6101 603-215
E-Mail: [email protected]
Or visit us on the Internet at www.stada.de/presse
Further information for capital market participants:
STADA Arzneimittel AG
Investor & Creditor Relations
Stadastraße 2-18
61118 Bad Vilbel
Tel.: +49 (0) 6101 603-4689
Fax: +49 (0) 6101 603-215
E-Mail: [email protected]
Or visit us online at
www.stada.de/investor-relations
Original content from: STADA Arzneimittel AG, transmitted by news aktuell